485-89-2 Usage
Description
Oxicinchophen is a compound with various pharmacological properties and applications in the field of medicine and biochemistry. It is known for its ability to interact with specific biological targets and modulate various cellular processes.
Uses
Used in Pharmaceutical Research:
Oxicinchophen is used as a research tool for studying P-selectin antagonistic activity, which is relevant in the context of inflammation and vascular biology. Its application in this area helps researchers understand the underlying mechanisms of these processes and develop potential therapeutic strategies.
Used in Enzyme Inhibition Studies:
Oxicinchophen is utilized as a DHOD (dihydroorotate dehydrogenase) inhibitor, which is an important enzyme in the pyrimidine biosynthesis pathway. Inhibition of this enzyme can have implications in the development of antiviral and anticancer drugs.
Used in Structure-Activity Relationship (SAR) Studies:
Oxicinchophen is employed in the investigation of the structure-activity relationship of quinoline salicylic acids using the Pfitzinger reaction of isatin derivatives with (acetyloxy)acetophenone derivatives. This helps in understanding the relationship between the chemical structure of these compounds and their biological activities.
Used in Anti-inflammatory Drug Research:
Oxicinchophen is used to study the effects of anti-inflammatory drugs on vascular smooth muscle. This application aids in the development of novel anti-inflammatory agents with improved efficacy and reduced side effects.
Used in Mitochondrial Function Studies:
Oxicinchophen is utilized to investigate the increase in oxygen consumption in the absence of a phosphate acceptor and to inhibit ATP synthesis in isolated rat liver mitochondria. This application provides insights into the role of oxycinchophen in cellular energy metabolism and its potential implications in various diseases related to mitochondrial dysfunction.
Safety Profile
Low toxicity by ingestion and skin contact. When heated to decomposition it emits toxic fumes of NOx.
Purification Methods
It is precipitated from alkaline solution on acidification and crystallises from EtOH or AcOH in yellow crystals. [Marshall & Blanchard J Pharmacol 95 186 1949, Beilstein 22 H 245, 22 II 183, 22 III/IV 2383.]
Check Digit Verification of cas no
The CAS Registry Mumber 485-89-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,8 and 5 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 485-89:
(5*4)+(4*8)+(3*5)+(2*8)+(1*9)=92
92 % 10 = 2
So 485-89-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H11NO3/c18-15-13(16(19)20)11-8-4-5-9-12(11)17-14(15)10-6-2-1-3-7-10/h1-9,18H,(H,19,20)
485-89-2Relevant articles and documents
Phosphorodiamidate-directed metalation of N -heterocycles using Mg- and Zn-TMP bases
Rohbogner, Christoph J.,Wirth, Stefan,Knochel, Paul
supporting information; experimental part, p. 1984 - 1987 (2010/07/15)
Figure presented The strong directing ability of the N,N,N′,N′- tetramethyldiaminophosphorodiamidate group has been used to achieve selective metalations on various heterocycles such as pyridines, quinolines and quinoxalines with TMP-derived bases like TMPMgCl·LiCl, TMP 2Mg·2LiCl, and TMP2Zn·2MgCl 2·2LiCl. This protocol was applied in the synthesis of etoricoxib, talnetant and a P-selectin inhibitor.
Multiple regioselective functionalizations of quinolines via magnesiations
Boudet, Nadege,Lachs, Jennifer R.,Knochel, Paul
, p. 5525 - 5528 (2008/09/17)
A wide range of polyfunctionalized quinolines was prepared via chemo- and regioselective magnesiation reactions using appropriate Mg reagents, such as i-PrMgCl-LiCl, MesMgBr·LiCl, Mes2Mg·2LiBr, TMPMgCl·LiCl, and TMP2Mg·2LiCl. An application to the total synthesis of the biologically active compound talnetant was performed (six steps, 28%).
Method for the synthesis of quinoline derivatives
-
Example 1, (2008/06/13)
This invention relates to novel intermediates and processes for preparing pharmaceutically active quinoline compounds, including (?)-(S)-N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide.
